Patents by Inventor Jeong Eun NA

Jeong Eun NA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11753376
    Abstract: The present specification discloses a novel benzyloxy pyridine derivative compound represented by Chemical Formula 1, a salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and novel uses thereof. The uses comprise the uses in the preparation of a composition for activating autophagy, a composition for activating p62 protein, a composition for inducing oligomerization of p62 protein, or a composition for ameliorating, preventing or treating a disease caused by misfolded protein.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: September 12, 2023
    Assignees: AUTOTAC INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Yong Tae Kwon, Hyun Tae Kim, Jeong Eun Na, Chang Hoon Ji, Chang An Jung
  • Publication number: 20230190938
    Abstract: One aspect of the disclosure relates to a cargo delivery system comprising an autophagy targeting ligand and a target-binding ligand. In one aspect of the disclosure, by comprising an autophagy targeting ligand, cargo, which is a target-binding ligand that specifically binds to a target, is delivered to the p62 protein and autophagy is activated, so that depending on the type of target-binding ligand used, a target to be degraded can be selectively and directly removed. Accordingly, the cargo delivery system according to an aspect of the disclosure may be used in pharmaceutical compositions or food compositions for preventing, alimerating, and treating various diseases.
    Type: Application
    Filed: February 15, 2023
    Publication date: June 22, 2023
    Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, PROTECH CO., LTD., AUTOTAC INC.
    Inventors: Yong Tae Kwon, Chang Hoon Ji, Srinivasrao Ganipisetti, Hee Yeon Kim, Su Ran Mun, Chan Hoon Jung, Eui Jung Jung, Ki Woon Sung, Hyun Tae Kim, Jeong Eun Na, Eun Hye Jeong, Ji Eun Lee, Min Ju Lee, Chang Min Park, Su Jin Kim
  • Publication number: 20230174465
    Abstract: The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Inventors: Yong Tae KWON, Hyun Tae KIM, Jeong Eun NA, Yu Jin SEO, Chang Hoon JI, Ha Rim CHOI, Ji Eun LEE, Ah Jung HEO
  • Publication number: 20230174470
    Abstract: The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Inventors: Yong Tae KWON, Hyun Tae KIM, Jeong Eun NA, Yu Jin SEO, Chang Hoon JI, Ha Rim CHOI, Ji Eun LEE, Ah Jung HEO
  • Publication number: 20220402873
    Abstract: Novel p62 ligand compounds, or a stereoisomer, a solvate, a hydrate, or a prodrug thereof are disclosed. The novel compounds, stereoisomer, solvate, hydrate, or prodrug activates selective autophagy in cells to selectively remove proteins, organelles, and coagulations in the body, and thus can be advantageously used as a pharmaceutical composition for preventing, ameliorating, or treating various proteinopathies. Compositions such as pharmaceutical composition or food compositions containing the novel p62 ligand compounds, stereoisomer, solvate, hydrate, or prodrug thereof as well as uses thereof are disclosed.
    Type: Application
    Filed: September 21, 2020
    Publication date: December 22, 2022
    Applicants: AUTOTAC INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Yong Tae KWON, Chang Hoon JI, Hyun Tae KIM, Jeong Eun NA, Hee Yeon KIM, Min Ju LEE
  • Publication number: 20220380346
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Publication number: 20220298113
    Abstract: The present specification discloses a novel benzyloxy pyridine derivative compound represented by Chemical Formula 1, a salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and novel uses thereof. The uses comprise the uses in the preparation of a composition for activating autophagy, a composition for activating p62 protein, a composition for inducing oligomerization of p62 protein, or a composition for ameliorating, preventing or treating a disease caused by misfolded protein.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 22, 2022
    Applicants: AUTOTAC INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Yong Tae KWON, Hyun Tae KIM, Jeong Eun NA, Chang Hoon JI, Chang An JUNG
  • Patent number: 11230539
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by absormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignee: CrystalGenomics, Inc.
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Publication number: 20210009565
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by absormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: February 14, 2020
    Publication date: January 14, 2021
    Inventors: Yong Rae HONG, Jeong Eun NA, Im Sook MIN, Hyun Ju CHA, Sool Ki KWON, Seonggu RO, Joong Myung CHO
  • Patent number: 10604508
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: March 31, 2020
    Assignee: CrystalGenomics, Inc.
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Publication number: 20170362205
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: August 30, 2017
    Publication date: December 21, 2017
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Patent number: 9758508
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: September 12, 2017
    Assignee: CrystalGenomics, Inc.
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Publication number: 20150336934
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: December 26, 2013
    Publication date: November 26, 2015
    Inventors: Yong Rae HONG, Jeong Eun NA, Im Sook MIN, Hyun Ju CHA, Sool Ki KWON, Seonggu RO, Joong Myung CHO